Latest Period
Q4 2025
CUSIP: 254604101
Latest Period
Q4 2025
Institutions Reporting
193
Shares (Excl. Options)
38,292,265
Price
$79.41
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
Latest holder context comes from 193 institutions filings for Q4 2025.
What is CUSIP 254604101?
CUSIP 254604101 identifies IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Use the next link that matches the question you still need to answer about this security.
Open recent reporting periods for CUSIP 254604101:
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | +16% | $324,265,066 | +$45,337,554 | 4,907,159 | +16% | FMR LLC | 30 Sep 2025 |
| AI DMI LLC | 8% | -25% | $199,459,837 | -$49,166,626 | 3,018,460 | -20% | AI DMI LLC | 20 Oct 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 5.9% | $177,001,530 | 2,228,924 | RA Capital Management, L.P. | 30 Dec 2025 | |||
| ORBIMED ADVISORS LLC | 4.5% | $73,382,798 | 1,556,369 | ORBIMED ADVISORS LLC | 10 Mar 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.1% | -39% | $79,996,547 | -$50,911,307 | 1,432,090 | -39% | Wellington Management Group LLP | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 3.5% | $57,097,283 | 1,210,971 | Paradigm BioCapital Advisors LP | 31 Mar 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 3% | $57,339,676 | 1,026,489 | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 3.3% | $46,372,025 | 983,500 | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2024 | |||
| Atlas Venture Fund X, L.P. | 2.2% | -30% | $73,469,638 | -$24,517,376 | 813,167 | -25% | Atlas Venture Fund X, L.P. | 12 Dec 2025 |
As of 31 Dec 2025, 193 institutional investors reported holding 38,292,265 shares of Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON). This represents 101% of the company’s total 37,778,373 outstanding shares.
The largest institutional shareholders of Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 5,450,222 | +10% | 0.02% | $432,802,132 |
| BlackRock, Inc. | 6% | 2,274,980 | +13% | 0% | $180,656,161 |
| RA CAPITAL MANAGEMENT, L.P. | 5.2% | 1,976,132 | +25% | 1.6% | $156,924,642 |
| VANGUARD GROUP INC | 4.7% | 1,767,680 | +22% | 0% | $140,371,470 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.5% | 1,698,005 | +28% | 0.01% | $134,839,000 |
| JPMORGAN CHASE & CO | 4.2% | 1,581,127 | +110% | 0.01% | $125,557,326 |
| WELLINGTON MANAGEMENT GROUP LLP | 4% | 1,518,274 | +7.7% | 0.02% | $120,566,138 |
| Atlas Venture Life Science Advisors, LLC | 4% | 1,513,875 | -29% | 14% | $120,216,814 |
| Frazier Life Sciences Management, L.P. | 3.3% | 1,260,000 | -12% | 2.7% | $100,056,600 |
| STATE STREET CORP | 3.1% | 1,187,991 | +14% | 0% | $94,338,365 |
| ORBIMED ADVISORS LLC | 2.8% | 1,067,550 | -25% | 1.8% | $84,774,146 |
| Siren, L.L.C. | 2.6% | 988,401 | +8.2% | 2.3% | $78,488,923 |
| Woodline Partners LP | 2.5% | 957,833 | +10% | 0.29% | $76,061,519 |
| GOLDMAN SACHS GROUP INC | 2% | 754,195 | +43% | 0.01% | $59,890,625 |
| Vestal Point Capital, LP | 1.9% | 735,000 | +47% | 2.1% | $58,366,350 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 684,958 | +9% | 0% | $54,402,165 |
| BVF INC/IL | 1.7% | 650,000 | 1.7% | $51,616,500 | |
| JENNISON ASSOCIATES LLC | 1.4% | 532,079 | 0.03% | $42,252,392 | |
| First Light Asset Management, LLC | 1.4% | 523,167 | +126% | 3.2% | $41,544,691 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.4% | 511,163 | -44% | 0.52% | $40,591,454 |
| Logos Global Management LP | 1.3% | 510,000 | +13% | 2.7% | $40,499,100 |
| ARMISTICE CAPITAL, LLC | 1.3% | 499,391 | +15% | 0.97% | $39,656,639 |
| Checkpoint Capital L.P. | 1.2% | 452,992 | +5.3% | 11% | $35,972,095 |
| PERCEPTIVE ADVISORS LLC | 1.2% | 450,743 | 0.66% | $35,793,502 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 1% | 395,392 | +28% | 0.49% | $31,397,693 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 35,860 | $2,293,135 | +$286,296 | $63.94 | 11 |
| 2025 Q4 | 38,292,265 | $3,040,364,773 | +$327,723,771 | $79.41 | 193 |
| 2025 Q3 | 34,174,573 | $2,258,188,476 | +$16,098,753 | $66.08 | 164 |
| 2025 Q2 | 34,069,403 | $1,804,405,782 | +$52,373,227 | $52.96 | 148 |
| 2025 Q1 | 33,154,047 | $1,649,828,469 | +$313,979,403 | $49.64 | 155 |
| 2024 Q4 | 26,576,603 | $1,684,756,023 | -$53,215,124 | $63.40 | 151 |
| 2024 Q3 | 27,309,249 | $1,342,089,295 | -$26,632,908 | $49.14 | 130 |
| 2024 Q2 | 27,576,793 | $1,242,993,864 | +$212,594,407 | $45.07 | 119 |
| 2024 Q1 | 22,155,328 | $1,379,374,874 | +$124,372,681 | $62.26 | 125 |
| 2023 Q4 | 20,197,167 | $1,166,592,879 | +$18,737,189 | $57.76 | 111 |
| 2023 Q3 | 19,879,838 | $933,957,855 | +$42,877,645 | $46.98 | 90 |
| 2023 Q2 | 19,115,397 | $848,710,699 | +$223,083,623 | $44.40 | 89 |
| 2023 Q1 | 14,612,435 | $309,637,635 | +$77,103,451 | $21.19 | 45 |
| 2022 Q4 | 10,800,037 | $214,639,221 | +$202,496,221 | $19.89 | 30 |